-- 
Baccarat, BioAlliance Pharma, Valeo: French Equity Preview

-- B y   G r e g o r y   V i s c u s i   a n d   M a r t h e   F o u r c a d e
-- 
2011-09-22T04:00:05Z

-- http://www.bloomberg.com/news/2011-09-21/baccarat-bioalliance-pharma-valeo-french-equity-preview.html
Shares in the following companies
may have unusual moves in Paris trading. Stock symbols are in
parentheses and prices are from the last close.  Franceâ€™s CAC 40 Index fell 1.6 percent to 2,935.82. The
broader SBF 120 Index fell 1.4 percent to 2,259.25.  Baccarat (BCRA)  SA: The crystal manufacturer said its
swung to a first-half net profit of 900,000 euros from a 611,000
euro year-ago loss. The shares rose 0.1 percent to 140.0 euros.  BioAlliance Pharma SA (BIO)  : The cancer drug developer
said it had a first-half loss of 8.75 million euros, compared
with net income of 10.58 million euros a year earlier. The
shares fell 1.8 percent to 3.36 euros.  Neurones (NRO)  SA: The computer services company said
first-half operating profit rose to 12.6 million euros from 10
million euros. The shares rose 0.4 percent to 7.28 euros.  Valeo SA (FR)  : The car parts maker said it bought back
558,302 shares at average price of 33.14 euros to cover bonuses
and stock options plans. The shares fell 5 percent to 34.44
euros.  Vinci SA (DG)  : The construction company said it and
Dutch builder Royal BAM Groep NV have finalized the financing
for updating a section of the Berlin to Munich highway, a 220
million euro project. The shares fell 1.1 percent to 32.79
euros.  To contact the reporter on this story:
Gregory Viscusi in Paris at 
 gviscusi@bloomberg.net 
Marthe Fourcade in Paris at 
 mfourcade@bloomberg.net   To contact the editor responsible for this story:
Andrew Rummer at 
 arummer@bloomberg.net  